Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Nutra Pharma
Drug Discovery
Medical Devices
Newsroom
Investor Relations
Corporate Overview
Contact
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Welcome to Nutra Pharma

 
Drug Discovery and Medical Devices
|||

Nutra Pharma Corp. operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. Additionally, the company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.

 
Drug Discovery

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Nyloxin®, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Nyloxin® is protected under patent #7,902,152, Use of cobratoxin as an analgesic. In December of 2014, the Company launched Pet Pain-Away - the first OTC product to treat pain in companion animals without side effects.

The Company is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Nutra Pharma has completed pre-clinical and animal models for their MS and HIV applications and are preparing to move into pivotal Phase II trials. Nutra Pharma's MS drug was recently granted Orphan Status by the FDA for the treatment of Pediatric Multiple Sclerosis. .

Learn More
 
 
Analyst Report

Nutra Pharma was recently featured in a Comprehensive report issued by See Thru Equities - an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report can be viewed on the following link:Download here

 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
September 14, 2016
Nutra Pharma Announces Manufacturing Alliance with Omnia Biologics to Produce RPI-78M for Clinical Trials in Pediatric Multiple Sclerosis


August 30, 2016
Nutra Pharma Announces Addition of Maj. Gen. Kenneth Dowd to its Advisory Board


August 16, 2016
Nutra Pharma Announces Additions to the Board of Directors and Management Team


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics